China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with US firm ImmunoGen, Inc. (Nasdaq: IMGN). Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company, and ImmunoGen will provide their proprietary linker-payload technology to create novel ADCs. No financial details were disclosed.
Biosion’s Proprietary Technologies
Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies, including the H³ antibody discovery platform, SynTracer high-throughput endocytosis platform, and Flexibody bispecific platform. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in Phase II for severe asthma and entering Phase II for atopic dermatitis.
Future Plans and Global Operations
Biosion and partners have plans to progress additional immune-oncology biologics and antibody-drug conjugates into clinical trials for oncology indications over the next year. Biosion has operations in the US, Australia, and China, positioning it to advance its pipeline globally.-Fineline Info & Tech
